Solid IPO Activity Still Likely Into Early 2027

U.S. operating companies raised a record $34B in Q3, more than in all of 2022, 2023, or 2024, taking year-to-date capital raised to $146B and above 2021’s full-year record. Despite that fundraising strength, the Nasdaq IPO Pulse fell to a six-month low in September, though the slowdown was described as far milder than prior cyclical downturns. A collapsed Iran ceasefire, rising energy prices, and a Fed rate hike pushed 10-year yields to about 5.3%, their highest level since 2002.

Analysis

The key divergence is between capital availability and IPO risk appetite: a strong aggregate fundraising total does not establish that new listings can clear at attractive valuations. If much of the capital came from follow-ons or established issuers, it may actually compete with IPOs for investor dollars while masking weaker demand for first-time offerings. Verify the issuance mix before treating the total as a forward indicator for IPOs.

Near term, higher real discount rates and energy-driven inflation risk pressure long-duration, cash-burning companies most; a renewed rise in yields could widen IPO discounts and increase withdrawal risk. The relative winners are cash-generative, lower-duration businesses and investors with liquidity to wait for repricing. Over 1–3 months, the decisive catalysts are the 10-year yield’s direction, energy-price persistence, and whether the IPO pipeline prices and trades well—not the headline fundraising aggregate. Over 6–18 months, sustained issuance would broaden financing options, but only if public-market returns restore confidence in exit valuations.

Contrarian point: record fundraising may look like a reopening signal, but could reflect issuers raising capital before financing conditions tighten further. The thesis weakens if yields retreat and multiple new listings price successfully without material first-day or subsequent losses; it strengthens if yields rise again, IPOs are pulled, or issuance is concentrated outside IPOs.

Key Decisions for Investors

• Avoid extrapolating aggregate capital raised into a broad IPO recovery; monitor issuance by IPO versus follow-on/private placement and the aftermarket performance of new listings before adding exposure.
• For a 1–3 month relative-value expression, consider underweighting the Renaissance IPO ETF (IPO) versus a broad-market benchmark rather than taking a large outright short. Reassess if the 10-year yield stabilizes or falls and new issues show durable demand; cut the relative underweight if that confirmation appears.
• Favor balance-sheet resilience and near-term cash generation over long-duration, funding-dependent growth exposure while energy inflation and rate expectations remain unsettled. Falsifiers: a sustained decline in yields, easing energy prices, or improving IPO pricing and post-listing performance.